GBPUSD Pound Jumps to 1.25, Markets Eye Autumn

GBPUSD pound increased to the highest level since September 22nd, 2016

Chart | Calendar   | TRADE NOW | GBPUSD

British Pound | Data | Chart | Calendar | Forecast | News

BUZ INVESTORS  The pound increased to the highest level since September 22nd, 2016 of $1.3 on Thursday, after the UK retail sales data came well above market expectations, rising the most in 15 months. The currency gained 0.5% around 10:30 AM London time. Historically, the British Pound reached an all time high of 2.86 in December of 1957 and a record low of 1.05 in February of 1985.

Trade Idea Wrap-up GBPUSD – Buy at 1.2945

Cable’s intra-day rally above indicated psychological resistance at 1.3000 confirms recent upmove has resumed and bullishness is seen for further gain to 1.3050, then 1.3075-80, however, near term overbought condition should prevent sharp move beyond 1.3100-10, risk from there has increased for a retreat to take place later.

In view of this, would not chase this rise here and would be prudent to buy cable on pullback as support at 1.2933 should limit downside and bring another upmove. Below 1.2900-10 would abort and signal top is formed instead, bring weakness towards support at 1.2866, however, price should stay above said support at 1.2844.



pound increased

British Pound

The GBPUSD spot exchange rate specifies how much one currency, the GBP, is currently worth in terms of the other, the USD. While the GBPUSD spot exchange rate is quoted and exchanged in the same day, the GBPUSD forward rate is quoted today but for delivery and payment on a specific future date. This page provides – British Pound – actual values, historical data, forecast, chart, statistics, economic calendar and news. British Pound – actual data, historical chart and calendar of releases – was last updated on May of 2017.
Actual Previous Highest Lowest Dates Unit Frequency
1.30 1.30 2.86 1.05 1957 – 2017 Daily
United Kingdom Markets Last Previous Highest Lowest Unit
Currency 1.29 1.29 2.86 1.05 [+]
Stock Market 7523.99 7386.63 7435.39 427.50 points [+]
Government Bond 10Y 1.09 1.16 16.09 0.52 percent [+]
30 Year Bond Yield 1.80 1.81 16.01 1.22 percent [+]
2 Year Note Yield 0.11 0.12 0.93 0.04 percent [+]
5 Year Note Yield 0.56 0.58 13.58 0.13 percent [+]

Like up on FACEBOOK


logo



major currencies: (EUR-USD) (USD-JPY) (USD-GBP) (USD-CHF), (USD-CAD), (AUD-USD) (USDCNY)




Buz Investors Oil prices rise as survey suggest The commodity is trading at $52.40 per barrel at 10:40 GMT this morning, 0.32% lower from the New York close. Crude oil witnessed a high of $52.70 per barrel and a low of $52.24 per barrel during the session. In the New York session yesterday, crude oil fell 1.24%

United States Crude Oil Stocks Change | Data | Chart | Calendar

Chart | Calendar   | TRADE NOW | CRUDE OIL

United States Crude Oil Stocks Change | Data | Chart | Calendar


source: tradingeconomics.com
BUZ INVESTORS Crude Oil Stocks Change Stocks of crude oil in the United States fell by 0.930 million barrels in the week ended April 28th, 2017, following a 3.641 million decrease in the previous period and compared to market expectations of a 2.333 million decline. Gasoline stocks rose by 0.191 million, compared to expectations of a 1.322 million increase. Crude Oil Stocks Change in the United States averaged 0.11 BBL/1Million from 1982 until 2017, reaching an all time high of 14.42 BBL/1Million in October of 2016 and a record low of -15.22 BBL/1Million in January of 1999.

Crude Oil Stocks Change

>>>TRADE NOW<<<

Stocks of crude oil refer to the weekly change of the crude oil supply situation. This page provides the latest reported value for – United States Crude Oil Stocks Change – plus previous releases, historical high and low, short-term forecast and long-term prediction, economic calendar, survey consensus and news. United States Crude Oil Stocks Change – actual data, historical chart and calendar of releases – was last updated on May of 2017.
RADCOM (NASDAQ: RDCM) is a first-mover and leading provider of NFV-ready service assurance and Customer Experience Management (

RADCOM Reports Fourth Quarter and Full Year 2016 Financial Results

Chart | Calendar   | TRADE NOW | RDCM

RADCOM Reports Fourth Quarter and Full Year 2016 Financial Results

BUZ INVESTORS RADCOM Reports Fourth Quarter   RADCOM Ltd. <span data-recalc-dims=(RDCM) today reported its financial results for the fourth quarter and fiscal year ended December 31, 2016." width="300" height="103" srcset="https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/03/download-Small-1.jpg?resize=300%2C103 300w, https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/03/download-Small-1.jpg?resize=768%2C263 768w, https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/03/download-Small-1.jpg?w=854 854w" sizes="(max-width: 300px) 100vw, 300px" />

BUZ INVESTORS RADCOM Reports Fourth Quarter   RADCOM Ltd. (RDCM) today reported its financial results for the fourth quarter and fiscal year ended December 31, 2016.

“The fourth quarter marked a strong end to a great year for the Company, highlighted by our ability to reach the high-end of our guidance range,” commented Mr. Yaron Ravkaie, RADCOM’s CEO.  “In 2016, we made great progress with our top-tier customer deployments, continued our engagement with other leading global carriers, and focused on preparing the company for future growth by boosting our senior management team and ramping up our engineering capabilities.  We believe we have laid a solid foundation during 2016 to continue our momentum, as evidenced by our initial 2017 revenue guidance range of $36-$39 million.”

Fourth Quarter 2016 Financial Highlights

  • Revenues: Total revenues for the fourth quarter were $8.0 million, up 196% compared to $2.7 million in the fourth quarter of 2015.
  • Net Loss: GAAP net loss for the period was approximately $0.7 million, or $0.06 loss per diluted share, compared to a loss of $2.1 million, or $0.25 loss per diluted share for the fourth quarter of 2015.
  • Non-GAAP Net Income/(Loss):  Non-GAAP net income for the period was approximately $0.4 million, or $0.04 per diluted share, compared to a loss of $(1.6) million, or $(0.19) per diluted share for the fourth quarter of 2015.Both GAAP and non-GAAP results for the fourth quarter of 2016 included a $552,000, or $0.05 per diluted share, benefit related to grants from the Israel Innovation Authority (formerly Office of the Chief Scientist) compared to $576,000, or $0.07 per diluted share, in the fourth quarter of 2015.
  • Balance sheet: As of December 31, 2016, the Company had cash and cash equivalents of $42.9 million and no debt.




RADCOM Reports Fourth Quarter

>>>>TRADE NOW<<<

Full Year 2016 Financial Highlights

  • Revenues: Total revenues for the full year 2016 were $29.5 million, up 58% compared to $18.7 million in the full year 2015.
  • Net Income/(Loss): GAAP net income for the full year 2016 was approximately $1.9 million, or $0.18 per diluted share, compared to a loss of $(923,000), or $(0.11) per diluted share for the full year 2015.
  • Non-GAAP Net Income:  Non-GAAP net income for the period was approximately $4.8 million or $0.44 per diluted share, for the full year 2016, compared to $656,000, or $0.07 per diluted share for the full year 2015.Both GAAP and non-GAAP results for the full year 2016 included a $1.7 million, or $0.16 per diluted share, benefit related to grants from the Israel Innovation Authority compared to $1.6 million, or $0.18 per diluted share, in 2015.

Earnings Conference Call
RADCOM’s management will hold an interactive conference call today at 8:00 AM Eastern Time (15:00 Israel Time) to discuss the results and to answer participants’ questions. To join the call, please call one of the following numbers approximately five minutes before the call is scheduled to begin:

From the US (toll-free): + 1-888-668-9141

From other locations: +972-3-918-0609

For those unable to listen to the call at the time, a replay will be available from February 15th on RADCOM’s website.

About RADCOM

RADCOM (NASDAQ: RDCM) is a first-mover and leading provider of NFV-ready service assurance and customer experience management solutions for Communications Service Providers (CSPs). RADCOM’s software – MaveriQ – continuously monitors network performance and quality of services, to optimize user experience for CSPs’ subscribers. RADCOM specializes in solutions for next-generation mobile and fixed networks, including LTE, VoLTE, IMS and others. MaveriQ enables CSPs to smoothly migrate their networks to NFV by assuring physical, NFV-based and hybrid networks. For more information, please visit www.radcom.com.

Non-GAAP Information

Certain non-GAAP financial measures are included in this press release. These non-GAAP financial measures are provided to enhance the reader’s overall understanding of the Company’s financial performance. By excluding non-cash stock-based compensation that has been expensed in accordance with ASC Topic 718, inventory write-off and  non-cash write-off of importation taxes, the Company’s non-GAAP results provide information to both management and investors that is useful in assessing the Company’s core operating performance and in evaluating and comparing the Company’s results of operations on a consistent basis from period to period. These non-GAAP financial measures are also used by management to evaluate financial results and to plan and forecast future periods.  The presentation of this additional information is not meant to be considered a substitute for the corresponding financial measures prepared in accordance with GAAP.

Risks Regarding Forward-Looking Statements

Certain statements made herein that use words such as “estimate,” “project,” “intend,” “expect,” “‘believe”, “may”, “might”, “predict”, “potential”, “anticipate”, “plan” or similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. For example, when the Company discusses its momentum and revenue guidance for 2017 it is using foward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that could cause the actual results, performance or achievements of the Company to be materially different from those that may be expressed or implied by such statements, including, among others, changes in general economic and business conditions and specifically, decline in the demand for the Company’s products, inability to timely develop and introduce new technologies, products and applications, and loss of market share and pressure on prices resulting from competition. For additional information regarding these and other risks and uncertainties associated with the Company’s business, reference is made to the Company’s reports filed from time to time with the U.S. Securities and Exchange Commission. The Company does not undertake to revise or update any forward-looking statements for any reason.

 

Like up on FACEBOOK


Ebates Coupons and Cash Back

Market quotes are powered by
TradingView.com



Tech Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )




OTHER RELATED STORIES 

VPR Brands, LP will be attending as well as speaking at the 2017 MoneyShow in Orlando

$VPRB LP Announces 2016 Fourth Quarter and Full Year Results

VPR Brands, LP Announces 2016 Fourth Quarter and Full Year Results

BUZ INVESTORS VPRB LP Announces 2016 Fourth Quarter VPR Brands, LP (OTC Pink:VPRB) released 2016 fourth quarter and full year revenue and financials. 2016 revenue totaled $1,580,676, which represents

BUZ INVESTORS   VPRB LP Announces 2016 Fourth Quarter  VPR Brands, LP (OTC Pink:VPRB) released 2016 fourth quarter and full year revenue and financials. 2016 revenue totaled $1,580,676, which represents a 4,620.85% increase over 2015 revenue of $342. For 2016, VPR Brands had a gross profit margin of 30.42%, gross profit of $480,852 and a net operating loss of $327,757.

Fourth quarter 2016 revenue totaled $972,322, representing a 59.82%​ increase over third quarter 2016 revenue of $608,354. Fourth quarter 2016 operating margins were down slightly compared to the third quarter 2016 to 29.03%, with $282,298 in gross profit and a net operating loss of $206,174.



VPRB LP Announces 2016 Fourth Quarter

“The acquisition we made in 2016 was a bold move that has added incremental business and value to the Company for the last half of 2016 and has given us a running start into 2017. We believe that the Company is now well positioned to take advantage of the growing cannabis market segment,” said Kevin Frija, CEO of VPR Brands, LP. “We will continue to stay focused on our mission of building long-term value for the Company, both organically or through additional acquisitions that make sense for the Company.”

“I couldn’t be more excited for our portfolio of brands, our team of people, our great clients, our strategic alliances and our growth potential within the rapidly expanding cannabis space. Although 2016 was a short year for us, I believe we have set a solid foundation for growth that we can build upon for years to come,” commented Daniel Hoff, COO of VPR Brands, LP.

Although our sales are not segregated by brand or product category, our primary revenue source is from vaporization devices specifically created for use with medical cannabis and recreational marijuana. These devices are specifically created for use with extract oils and concentrates which are vaped, providing optimal results and the best experience for patients and recreational users. Vaporizers are far more convenient and discrete compared to traditional cannabis use methods. These units are compact, easy to carry and concealable. Modern cannabis vaporizers do not emit distinct and lingering odors that are affiliated with traditional marijuana use. We believe that portable vaporizers as the fastest growing delivery mechanism for marijuana. Our team is currently working with other market leaders within cannabis growth and extraction to innovate and further educate the marketplace on its advantages.

About VPR Brands LP:
VPR Brands is a technology company; whose assets include issued U.S. and Chinese patents for atomization related products including technology for medical marijuana vaporizers and electronic cigarette products and components. The Company is also engaged in product development for the vapor or vaping market, including e-liquids, vaporizers and electronic cigarettes (also known as e-cigarettes) which are devices which deliver nicotine and or cannabis through atomization or vaping, and without smoke and other chemical constituents typically found in traditional products. For more information about VPR Brands, please visit the Company on the web at www.vprbrands.com.Like up on FACEBOOK


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




PBOC's Ma says China should Switch its attention From GDP in the future

China 2016 GDP Growth Weakest in 26 Years

China 2016 GDP Growth Weakest in 26 Years


source: tradingeconomics.com
BUZ INVESTORS  China 2016 GDP Growth The Chinese economy expanded 6.7 percent in 2016, lower than a 6.9 percent growth in 2015. It was the weakest full-year expansion since 1990 but within the government’s target range of 6.5 to 7 percent, as investment and consumption growth has softened.

In 2016, services sector/tertiary industry rose 7.8 percent; easing from 8.3 percent in 2015 and accounting for 51.6 percent of GDP, up 1.4 percentage points. Manufacturing and construction/secondary industry grew by 6.1 percent, compared to a 6 percent a year earlier.




China 2016 GDP Growth

Final consumption expenditure accounted for 64.6 percent of GDP, lower than 66.4 percent in the preceding year. Meanwhile, capital formation contributed 42.2 percent while net exports were a 6.8 percent drag on growth.

Investment in fixed assets (excluding rural households) grew by 8.1 percent, the least since 1999, following a 10 percent last year. Investment by the state holding enterprises increased by 18.7 percent (vs 10.9 percent in 2015) while those of private investment went up by 3.2 percent (vs 10.1 percent in 2015).

Total retail sales of consumer goods rose 10.4 percent, slower than 10.7 percent in 2015. Sales in urban areas grew by 10.4 percent and those in rural by 10.9 percent. Online retail sales rose 26.2 percent versus 33.3 percent the prior year. Retail sales of physical goods increased of 25.6 percent from 31.6 percent in 2015, accounting for 12.6 percent of the total sales of consumer goods.
Total value of imports and exports in yuan terms decreased by 0.9 percent comapred to 7.0 percent decline in a year earlier, with exports dropping 2.0 percent while imports going up by 0.6 percent.
In the December quarter, the economy expanded 6.8 percent, compared to a 6.7 percent growth in the previous three quarters while markets expected a 6.7 percent expansion. It was the strongest growth since the fourth quarter 2015, supported by strong consumer spending, higher government  expenditure and robust bank lending.

On a quarterly basis, the GDP advanced 1.7 percent, compared to a 1.8 percent growth in the previous three months. It was the weakest expansion since the March quarter 2016.

Like up on FACEBOOK


Ebates Coupons and Cash Back



major currencies: (EUR-USD) (USD-JPY) (USD-GBP) (USD-CHF), (USD-CAD), (AUD-USD)


Buz Investors PIERIS PHARMACEUTICALS REPORTS FULL-YEAR 2016

PIERIS PHARMACEUTICALS REPORTS FULL-YEAR 2016 FINANCIAL RESULTS AND CORPORATE UPDATE

PIERIS PHARMACEUTICALS REPORTS FULL-YEAR 2016 FINANCIAL RESULTS AND CORPORATE UPDATE

Download PDF

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, MARCH 23, 2017 AT 10:00 AM EDT

Buz Investors PIERIS PHARMACEUTICALS REPORTS FULL-YEAR 2016

Buz Investors PIERIS PHARMACEUTICALS REPORTS FULL-YEAR 2016   — Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, today reported financial results for the fourth quarter and fiscal year of 2016 and provided an update on the Company’s recent developments.




OTHER STORIES BUZ TRADERS FOLLOW

PIERIS PHARMACEUTICALS REPORTS FULL-YEAR 2016  

“2016 was a highly productive year for Pieris marked by: i) broad advancement of our proprietary clinical and preclinical programs, ii) completion of a $16.5 million private placement financing that strengthened our shareholder base, iii) achievement of several milestones in our collaborative programs, and iv) expansion of our Board of Directors and the appointment of a Chief Business Officer. At several R&D conferences throughout the year, including in the fourth quarter at the annual meeting of the Society of Immunotherapy of Cancer (SITC), we presented preclinical data demonstrating a differentiated mode of action for PRS-343, our lead 4-1BB (CD137)-based HER-2 bispecific immuno-oncology program, which remains on track for Phase I initiation in the first half of this year,” said Stephen Yoder, President and CEO. “Our targeted, inhaled asthma program, PRS-060, which engages the IL4a receptor, is differentiated from systemically administered therapies, and is on track to enter a Phase I study in mid-2017. Pieris has also completed dosing of all patients in a Phase Ib single ascending dose study of our most advanced program, PRS-080, in dialysis-dependent chronic kidney disease patients and expects to present this data in the first half of this year.”

“With these accomplishments behind us, we started 2017 on a very strong note, as we have already consummated a multi-target, multi-year, transformative partnership in the immuno-oncology space with Servier, the second largest pharmaceutical company in France. This alliance includes our dual checkpoint inhibitor, PRS-332, as well as four additional bispecific programs and may be expanded to eight total programs. Notably, Pieris has the option to co-develop and retain full US rights for four of these programs, including PRS-332, and is eligible to receive up to approximately $1.8 billion in total potential milestones, and up to low double-digit royalties on potential future product sales, in addition to having received an upfront payment of approximately $31.0 million. We also recently announced a regional partnership in Japan with Aska Pharmaceutical Co., Ltd. for PRS-080, which will allow us to invest in manufacturing efficiencies and drug supply for additional clinical studies beyond our planned Phase IIa study, which we believe could help set the stage for additional potential partnerships outside of Japan, following the completion of that study. Finally, we continue to advance our preclinical portfolio of novel multispecific therapeutic proteins, as well as our existing partnerships, while continuing to explore additional collaborations. We ended the fourth quarter in a solid financial position and, considering the upfront payments we have received in the first quarter of 2017, we believe we can manage our financial runway into 2019, enabling us to reach several key value inflection points along the way.”

Fourth Quarter and 2016 Highlights:

  • Advanced PRS-080 through an ongoing Phase Ib single ascending dose study in anemia of chronic disease, having completed patient dosing in early 2017, which will assess the effect of PRS-080 on iron mobilization and transferring saturation in dialysis-dependent anemia patients.
  • Advanced PRS-343 through IND-enabling studies and towards a first-in-patient study for HER-2 positive cancers.
  • Advanced PRS-060, a novel inhaled therapeutic for moderate to severe asthma, through IND-enabling studies.
  • Advanced our novel multi-checkpoint blockade bispecific, PRS-332, comprised of an anti-PD-1 antibody genetically linked to an existing Anticalin against an undisclosed checkpoint, through preclinical studies.
  • Strengthened our Board of Directors with the addition of Julian Adams, Ph.D. and Christopher Kiritsy.
    • Dr. Adams is the former President of Research & Development at Infinity Pharmaceuticals. During his career, Dr. Adams has had global responsibility for multiple drug discovery programs, including the discovery and development of Velcade® (bortezomib), a proteasome inhibitor for cancer therapy, and Viramune® (nevirapine) for HIV. Dr. Adams has received many awards, including the 2012 Warren Alpert Foundation Prize for his role in the discovery and development of bortezomib, the 2012 C. Chester Stock Award Lectureship from Memorial Sloan-Kettering Cancer Center, and the 2001 Ribbon of Hope Award for Velcade® from the International Myeloma Foundation.
    • Mr. Kiritsy is the Chief Executive Officer and co-founder of Arisaph Pharmaceuticals. Prior to Arisaph, Mr. Kiritsy served as Executive Vice President, Corporate Development and Chief Financial Officer of Kos Pharmaceuticals, Inc., where he played a key operating role in building the company from start-up to a highly profitable, publicly traded, commercial company.
  • Appointed Claude Knopf as Senior Vice President and Chief Business Officer. Prior to joining Pieris, Mr. Knopf served as Global Head Business Development & Licensing/Mergers and Acquisitions at Baxalta. Prior to joining Baxalta, a spin-off of Baxter where he held a similar position for the Baxter Bioscience Division up to the creation of Baxalta. Prior to joining Baxter, Mr. Knopf held several business development, alliance management, and licensing and marketing roles at Novartis, most recently as the Head of Business Development and Licensing, Strategic Planning, Vaccines European Region.

Fiscal Year Financial Update:

Cash Position – Cash and cash equivalents totalled $29.4 million as of December 31, 2016, compared to $29.3 million as of December 31, 2015. The increase in cash was driven primarily by the $16.5 million gross private placement financing completed in June 2016 offset by cash used in our operating activities.

R&D Expense ­ – Research and development expenses were $19.7 million for the year ended December 31, 2016, compared to $8.2 million for the year ended December 31, 2015. The $11.5 million increase was primarily due to a $5.6 million increase in pre-clinical development and CMC costs for PRS-343 as we carry out IND enabling studies and increased development costs for our other PRS-300 series programs, and a $1.2 million increase in CMC costs associated with PRS-060 as we carry out IND enabling studies, offset by a $0.2 million decrease for our PRS-080 program due to the completion of our Phase Ia clinical trial in 2015. Other R&D expenses also increased by $4.9 million primarily due to higher personnel-related expenses including stock-based compensation expense and increased costs for license fees, as well as higher legal and consulting costs. Additionally, costs for general lab supplies increased due to an upturn in program activities.

G&A Expense – General and administrative expenses for the year ended December 31, 2016 were $8.9 million, compared to $8.4 million for the year ended December 31, 2015. The $0.5 million increase in G&A expenses is primarily due to an increase in personnel-related costs, including stock-based compensation expense, higher legal and recruiting costs, and costs associated with being a public company such as financial printing costs and transaction fees.

Net Loss – Net loss was $22.8 million or ($0.55) per share for the year ended December 31, 2016, compared to a net loss $14.1 million or ($0.41) per share for the year ended December 31, 2015.

Upcoming Milestones:

The Company expects to reach the following milestones during 2017:

  • PRS-080: Present Phase Ib data and initiate a multi-dose, Phase IIa study in dialysis-dependent anemia patients during the second quarter, which we estimate will be completed by the end of 2017.
  • PRS-343: Initiate a Phase I multi-ascending dose study involving a range of HER2-positive solid cancers representing unmet medical needs (such as breast, gastrointestinal and bladder cancers) in the first half of 2017.
  • PRS-332: Progress preclinical evaluation in collaboration with Servier, with IND-enabling activities planned for later in 2017.
  • PRS-060: Initiate a Phase I study in mid-2017.

Upcoming Scientific Presentations:

  • PRS-343: IND-enabling data informing the design of a first-in-patient clinical trial for PRS-343 will be presented in a poster session at next month’s Annual Meeting of the American Association for Cancer Research (AACR) to be held in Washington D.C. The poster will be presented on Tuesday, April 4, 2017 in a session from 8am to 12pm EDT.

Conference Call:

Pieris management will host a conference call beginning at 10:00 AM Eastern Daylight Time on Thursday, March 23, 2017, to discuss the full year financial results and provide a corporate update. You can join the call by dialing +1-877-407-8920 (US & Canada) or +1-412-902-1010 (International). An archived replay of the call will be available by dialling +1-877-660-6853 (US & Canada) or +1-201-612-7415 (International) and providing the Conference ID #: 13657695.

About Pieris Pharmaceuticals :

Pieris is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris. Pieris has partnerships with Servier, ASKA, Roche, Sanofi, Daiichi Sankyo and Zydus. For more information visit www.pieris.com.


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Australian house price index advanced less than expected in 2Q 2016

Australian house price index climbed more than expected in 4Q 2016

Australian house price index climbed more than expected in 4Q 2016

Australian house price index advanced less than expected in 2Q 2016

Buz Investors Australian house price index Residential property prices in Australia rose jumped 4.1 percent quarter-on-quarter in the three months to December of 2016, following a 1.5 percent gain in the third quarter and beating market consensus of a 2.4 percent rise. It was the fastest increase since the June quarter 2015, as prices went up in most cities: Melbourne (5.3 percent from 1.7 percent in the prior quarter), Sydney (5.2 percent from 2.6 percent), Hobart (4.5 percent from 2.3 percent), Canberra (2.8 percent from 0.8 percent), Brisbane (2.2 percent from 0.2 percent), Adelaide (1.8 percent from 0.9 percent) and Perth (0.3 percent from -1.6 percent). In contrast, prices fell in Darwin (-1.5 percent from -1.2 percent). On a yearly basis, house prices grew by 7.7 percent, compared to a 3.5 percent rise in the previous quarter. Housing Index in Australia averaged 1.69 percent from 2002 until 2016, reaching an all time high of 6.10 percent in the second quarter of 2002 and a record low of -2.60 percent in the third quarter of 2008.



OTHER STORIES BUZ TRADERS SHARE

Australian house price index

In Australia, House Price Index measures weighted average of price movements for residential properties for eight capital cities: Sydney, Melbourne, Brisbane, Adelaide, Canberra, Hobart, Darwin and Perth. Residential properties are defined as detached residential dwellings on their own block of land regardless of age. . This page provides the latest reported value for – Australia House Price Index – plus previous releases, historical high and low, short-term forecast and long-term prediction, economic calendar, survey consensus and news. Australia House Price Index – actual data, historical chart and calendar of releases – was last updated on March of 2017.


Ebates Coupons and Cash Back



major currencies: (EUR-USD) (USD-JPY) (USD-GBP) (USD-CHF), (USD-CAD), (AUD-USD)




Buz Investors Ryerson Reports Fourth Quarter (NYSE: RYI), a leading distributor and value-added processor of industrial metals, today reported results for the fourth quarter and full-year ended December 31, 2016.

Ryerson Reports Fourth Quarter and Full-Year 2016 Results

Increased Earnings with Market Share Gains and Improved Capital Structure

Buz Investors Ryerson Reports Fourth Quarter (NYSE: RYI), a leading distributor and value-added processor of industrial metals, today reported results for the fourth quarter and full-year ended December 31, 2016.

Buz Investors Ryerson Reports Fourth Quarter (NYSE: RYI), a leading distributor and value-added processor of industrial metals, today reported results for the fourth quarter and full-year ended December 31, 2016.

Eddie Lehner, Ryerson’s President and Chief Executive Officer said, “I want to send a resounding thank you to our customers for giving us the opportunity to earn their business and support their growth. I also want to thank the Ryerson Team for a job well done in navigating through persistent demand contraction and selling price deflation through the first half of 2016.  Our improved financial performance is the result of our passion for the customer experience, as we continue our company transformation as an intelligent network of service centers whose common core is built around speed, scale, value-add, culture, and analytics. During 2016 Ryerson increased market share, expanded gross margins, reduced costs, reduced interest expense, grew net income and EBITDA, improved working capital efficiency, reduced debt, and strengthened our capital structure, a list worthy of repeating on an annual basis.”



OTHER STORIES BUZ TRADERS FOLLOW

Ryerson Reports Fourth Quarter

 

2016 Results
Revenues were $2.9 billion in 2016, down 9.7 percent from 2015, as average selling price per ton declined by 10.0 percent.

Gross margin increased to 20.0 percent in 2016, compared to 17.9 percent in 2015. Included in cost of materials sold was net LIFO income of $6.6 million in 2016 and $59.5 million in 2015. Gross margin, excluding LIFO increased to 19.7 percent in 2016, compared with 16.0 percent in 2015. A reconciliation of gross margin, excluding LIFO to gross margin is included below in this news release.

Warehousing, delivery, selling, general and administrative expense declined by $14.4 million, or 3.2 percent in 2016, compared to the year-ago period, reflecting continued expense management and operational efficiencies.

Net income attributable to Ryerson Holding Corporation improved to $18.7 million, or $0.54 per diluted share, in 2016, compared with a loss of $0.5 million, or $0.02 per diluted share, in 2015. Excluding restructuring and other charges, impairment charges on assets, and gains or losses on the retirement of debt, net income attributable to Ryerson Holding Corporation increased to $28.0 million, or $0.81 per diluted share, in 2016 compared to $16.1 million, or $0.50 per diluted share, in 2015. A reconciliation of net income attributable to Ryerson Holding Corporation and earnings per share, excluding restructuring and other charges, impairment charges on assets and gains or losses on retirement of debt is included below in this news release.

Adjusted EBITDA, excluding LIFO increased 63.3 percent to $178.0 million in 2016, compared to $109.0 million in 2015. Reconciliations of Adjusted EBITDA, excluding LIFO and net income attributable to Ryerson Holding Corporation are included below in this news release.

Balance Sheet Deleveraging and Working Capital Management
In 2016, Ryerson issued $650 million of Senior Secured Notes due 2022, issued common stock with net proceeds of $71.5 million used to further pay down debt, and amended its credit facility, thereby extending the maturity date to November 2021. “We’ve significantly improved our capital structure by reducing our debt by $279 million, or 22.4 percent, since 2014,” said Erich Schnaufer, Ryerson’s Chief Financial Officer.

In 2016, Ryerson’s inventory balance stood at 76 days of supply compared to 80 days in the year-ago period. “Our continued industry-leading working capital management provides financial flexibility and allows us to effectively adapt in volatile metal pricing environments,” continued Schnaufer.

Fourth Quarter 2016 Results
Revenues were $682.2 million for the fourth quarter of 2016, up 2.0 percent from the year-ago period. Tons shipped per day increased 1.4 percent with one fewer shipping day in the fourth quarter of 2016, and the average selling price per ton increased 2.2 percent from the fourth quarter of 2015.

Gross margin increased to 16.8 percent for the fourth quarter of 2016, compared to 15.2 percent for the year-ago period. Included in cost of materials sold was net LIFO expense of $13.8 million for the fourth quarter of 2016 and $10.8 million for the fourth quarter of 2015. Gross margin, excluding LIFO increased to 18.8 percent for the fourth quarter of 2016, compared with 16.8 percent for the year-ago period. A reconciliation of gross margin to gross margin, excluding LIFO is included below in this news release.

Warehousing, delivery, selling, general and administrative expense declined by $2.5 million, or 2.3 percent, for the fourth quarter of 2016 compared to the year-ago period, reflecting continued progress on expense management and operational efficiencies.

The net loss attributable to Ryerson Holding Corporation was $8.6 million, or $0.23 per diluted share, for the fourth quarter of 2016, compared to a net loss of $20.5 million, or $0.64 per diluted share, in the fourth quarter of 2015. Excluding restructuring and other charges, impairment charges on assets, and gains or losses on the retirement of debt, the net loss attributable to Ryerson Holding Corporation was $7.1 million, or $0.19 per diluted share, for the fourth quarter of 2016, compared to a loss of $12.9 million, or $0.40 per diluted share, in the fourth quarter of 2015.

Adjusted EBITDA, excluding LIFO was $36.0 million in the fourth quarter of 2016, compared to $14.2 million in the year-ago period. Reconciliations of Adjusted EBITDA, excluding LIFO and net income attributable to Ryerson Holding Corporation and earnings per share, excluding restructuring and other charges, impairment charges on assets, and gains or losses on retirement of debt to net income attributable to Ryerson Holding Corporation are included below in this news release.

2017 Acquisitions
In January 2017, Ryerson announced the acquisition of The Laserflex Corporation, a metal fabricator specializing in laser fabrication and welding services, with annual revenue of approximately $25 million. In addition, Ryerson announced a second acquisition in February 2017 of Guy Metals, Inc., a metal service center processing stainless and nickel alloy products, with annual revenue of approximately $35 million.  “The acquisition of these competitively differentiated companies that offer industry-leading fabrication, polishing, and processing capabilities perfectly aligns with our transformational strategy. These organizations are well matched to our common core of speed, scale, value-add, culture, and analytics.  We are excited to add their products and capabilities across our North American service center network,” said Lehner.

2017 Commentary
Ryerson intends to issue first quarter 2017 guidance in early April after LIFO and LCM reserve outcomes can be more accurately estimated given significant increases in industrial metals prices over the past four months.  Qualitatively, demand has improved in oil & gas most notably while other end markets in aggregate are showing modest if unspectacular improvement.  The better story thus far is supply side stabilization as policy lines have drawn a playing field in which prices are better supported as we move through the quarter.




Buz Investors Tabula Rasa HealthCare (“TRHC”) (NASDAQ:TRHC), a disruptive innovation and technology leader in medication safety, offering a unique Medication

Tabula Rasa HealthCare Announces Fourth Quarter and Full Year 2016 Operating Results

Tabula Rasa HealthCare Announces Fourth Quarter and Full Year 2016 Operating Results

2016 Revenue of $94.1 million, growth of 34%; 4Q 2016 Revenue of $27.3 million, growth of 38%

Buz Investors Tabula Rasa HealthCare (“TRHC”) <span data-recalc-dims=(NASDAQ:TRHC), a disruptive innovation and technology leader in medication safety, offering a unique Medication" width="300" height="169" srcset="https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/03/maxresdefault-1.jpg?resize=300%2C169 300w, https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/03/maxresdefault-1.jpg?resize=768%2C432 768w, https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/03/maxresdefault-1.jpg?resize=1024%2C576 1024w, https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/03/maxresdefault-1.jpg?w=1280 1280w, https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/03/maxresdefault-1.jpg?w=1920 1920w" sizes="(max-width: 300px) 100vw, 300px" />

Buz Investors Tabula Rasa HealthCare (“TRHC”) (NASDAQ:TRHC), a disruptive innovation and technology leader in medication safety, offering a unique Medication Risk Stratification and Medication Risk Mitigation Matrix® suite of decision support tools, today announced its financial results for the fourth quarter and full year ended December 31, 2016 and provided its 2017 financial outlook.

TRHC Chairman and CEO, Calvin H. Knowlton, PhD., commented, “2016 was very exciting for Tabula Rasa and we ended the year with strong fourth quarter revenue and Adjusted EBITDA growth. Our core Program for All-Inclusive Care for the Elderly (“PACE”) market continued to expand overall, and our PACE contracts are performing well as we execute on our goal of helping our partners improve patient outcomes and lower cost.”



OTHER STORIES BUZ TRADERS FOLLOW

Tabula Rasa HealthCare

Dr. Knowlton continued, “On January 1, we launched our Enhanced Medication Therapy Management Programi and have seen strong initial engagement from our health plan members. We continue to find new and exciting markets where we can apply our propriety medication risk mitigation platform across the healthcare continuum. Our pipeline of new business opportunities, both within PACE and in the broader healthcare market, has never been stronger. I look forward to continuing to update you on the evolution and progress of our company and our technology throughout 2017.”

Financial Performance for the Three Months Ended December 31, 2016

All comparisons, unless otherwise noted, are to the three months ended December 31, 2015.

  • Total revenue was $27.3 million, an increase of 38%. Total revenue included product revenue of $20.7 million, an increase of 19%, and service revenue of $6.6 million, an increase of 177%.
  • Gross margin was 34%, compared to 30%. The year over year increase is primarily related to the two non-recurring projects with payors that were previously announced.
  • Non-GAAP Adjusted EBITDA was $4.8 million, compared to $2.4 million, an increase of 101% compared to a year ago. Adjusted EBITDA margin of 18% in the fourth quarter of 2016 compared favorably to 12% during the same period in 2015. Adjusted EBITDA was also favorably impacted by the two non-recurring contracts with payors.
  • Net loss was $6.0 million, compared to net income of $1.1 million. Fourth quarter 2016 included a $5.0 million expense related to the early extinguishment of debt as well as $3.4 million of incremental stock-based compensation expense related to restricted stock grants and shares issued in connection with TRHC’s initial public offering.
  • Net loss per diluted share was $0.39, compared to net income per diluted share of $0.03. The net loss and net income per share calculations were based on a diluted share count of 15.4 million for the fourth quarter of 2016, compared to 12.4 million shares a year ago.
  • Non-GAAP Adjusted net income per diluted share was $0.10, compared to a net loss per share of $0.01.

Financial Performance for the Twelve Months Ended December 31, 2016

All comparisons, unless otherwise noted, are to the twelve months ended December 31, 2015.

  • Total revenue was $94.1 million, an increase of 34%. Total revenue included product revenue of $79.4 million, an increase of 32%, and service revenue of $14.6 million, an increase of 47%.
  • Gross margin was 31%, compared to 30%. The year over year increase is primarily related to the two non-recurring projects with payors.
  • Non-GAAP Adjusted EBITDA was $13.6 million, compared to $8.6 million, an increase of 58% compared to a year ago. Adjusted EBITDA margin of 14.5% in 2016 compared favorably to 12.3% in 2015. Adjusted EBITDA was also favorably impacted by the two non-recurring contracts with payors.
  • Net loss was $6.3 million, compared to a net loss of $2.9 million. Full year 2016 included $6.4 million of expense related to the early extinguishment of debt, $4.5 million of interest expense and $3.5 million of incremental stock-based compensation expense related to restricted stock grants and shares issued in connection with TRHC’s initial public offering.
  • Net loss per diluted share was $0.59, compared to a net loss per share of $2.97. The net loss per share calculations were based on a diluted share count of 11.6 million for the full year 2016, compared to 4.3 million shares a year ago.
  • Non-GAAP Adjusted net income per diluted share was $0.19, compared to a net loss per share of $0.07.

A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. Non-GAAP results exclude change in fair value of warrant liability, loss on extinguishment of debt, change in fair value of acquisition-related contingent consideration (income) expense, change in fair value of acquisition-related consideration expense, and stock-based compensation expense. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures”.

Business Outlook

First Quarter 2017 Guidance: Revenue for TRHC’s first quarter 2017 is expected to be in the range of $25.5 million to $26.5 million. Net loss is expected to be in the range of $1.6 million to $3.1 million. Net loss projections include incremental stock-based compensation expense of approximately $3.1 million related to restricted stock grants issued in connection with TRHC’s initial public offering. Adjusted EBITDA is expected to be in the range of $2.5 million to $3.0 million.

Full Year 2017 Guidance: Revenue for fiscal year 2017 is expected to be in the range of $116.0 million to $118.0 million. Net income (loss) is expected to be in the range of a net loss of $0.5 million to net income of $0.9 million. Net income (loss) projections include incremental stock-based compensation expense of approximately $5.2 million related to restricted stock grants issued in connection with TRHC’s initial public offering, which will be fully expensed by May 2017. There are no debt extinguishment charges anticipated in 2017. Adjusted EBITDA is expected to be in the range of $15.5 million to $17.0 million.

Quarterly Conference Call

As previously announced, TRHC will hold a conference call with members of executive management to discuss its fourth quarter and full year 2016 performance today, Monday, March 13, 2017, at 5:00 p.m. EDT. Stockholders and interested participants may listen to a live broadcast of the conference call by dialing 844-413-0947 or 216-562-0423 for international callers, and referencing participant code 64870364 approximately 15 minutes prior to the call. A live webcast of the conference call will be available on the investor relations section of TRHC’s website at ir.trhc.com and an audio file of the call will also be archived and available for replay approximately two hours after the live event for a period of 90 days thereafter at ir.trhc.com. After the conference call, a replay will be available until April 12, 2017 and can be accessed by dialing 855-859-2056 or 404-537-3406 for international callers, and referencing participant code 64870364.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Since 2011, TRHC has focused on optimizing outcomes for PACE and other healthcare organizations through its unique Medication Risk Mitigation software and Medication Decision Support and Adherence tools that personalize each participant’s medication regimen.  For more information, please visit: www.TRHC.com.

Non-GAAP Financial Measures

In addition to reporting all financial information required in accordance with accounting principles generally accepted in the United States of America (GAAP), TRHC is also reporting Adjusted EBITDA and Adjusted Diluted EPS, each of which is a non-GAAP financial measure. Generally, a non-GAAP financial measure is a numerical measure of a company’s performance or financial position that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.

Adjusted EBITDA consists of net income (loss) plus certain other expenses, which includes change in fair value of warrant liability, interest expense, loss on extinguishment of debt, provision (benefit) for income tax, depreciation and amortization, change in fair value of acquisition-related contingent consideration (income) expense, change in fair value of acquisition-related consideration expense, and stock-based compensation expense. TRHC defines Adjusted Diluted EPS as net income (loss) attributable to common stockholders before accretion of redeemable convertible preferred stock, fair value adjustments related to the remeasurement of warrant liabilities, losses on the extinguishment of debt, fair value adjustments for acquisition-related contingent consideration, fair value adjustments for acquisition-related consideration, stock-based compensation expense, and the tax impact of those items expressed on a per share basis using weighted average diluted shares outstanding. TRHC believes the exclusion of these items assists in providing a more complete understanding of the company’s underlying operations results and trends and allows for comparability with TRHC’s peer company index and industry and to be more consistent with TRHC’s expected capital structure on a going forward basis. Please note that other companies might define their non-GAAP financial measures differently than TRHC does.

TRHC presents these non-GAAP financial measures in this release because it considers them to be important supplemental measures of performance. TRHC uses these non-GAAP financial measures for planning purposes, including analysis of the company’s performance against prior periods, the preparation of operating budgets and determination of appropriate levels of operating and capital investments. TRHC believes that these non-GAAP financial measures provide additional insight for analysts and investors in evaluating the company’s financial and operational performance. TRHC also intends to provide these non-GAAP financial measures as part of the company’s future earnings discussions and, therefore, their inclusion should provide consistency in the company’s financial reporting.

Non-GAAP financial measures have limitations as an analytical tool. Investors are encouraged to review the reconciliation of the non-GAAP measures to their most directly comparable GAAP measures provided in this release, including in the accompanying tables.

Safe Harbor Statement

This press release includes forward-looking statements that we believe to be reasonable as of today’s date.  Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions.  These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release.  Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: our continuing losses and need to achieve profitability; fluctuations in our financial results; the acceptance and use of our products and services by PACE organizations; the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; our ability to maintain relationships with a specified drug wholesaler; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; the requirements of being a public company; our ability to recognize the expected benefits from acquisitions on a timely basis or at all; our status as an “emerging growth company”; and the other risk factors set forth from time to time in our filings with the Securities and Exchange Commission (“SEC”),  including those factors discussed under the caption “Risk Factors” in our prospectus, filed with the SEC on September 29, 2016, pursuant to Rule 424(b) under the Securities Act, copies of which are available free of charge within the Investor Relations section of the Tabula Rasa HealthCare website http://ir.tabularasahealthcare.com or upon request from our Investor Relations Department. Tabula Rasa HealthCare assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.